The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-11), Shandong Boan Biotechnology Co's share price is €0.52.
Shandong Boan Biotechnology Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00. Therefore, Shandong Boan Biotechnology Co's PE Ratio without NRI for today is 520.00.
During the past 6 years, Shandong Boan Biotechnology Co's highest PE Ratio without NRI was 948.00. The lowest was 54.97. And the median was 86.11.
Shandong Boan Biotechnology Co (FRA:UJ9) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Shandong Boan Biotechnology Co PE Ratio without NRI Related Terms
Shandong Boan Biotechnology Co PE Ratio without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Boan Biotechnology Co PE Ratio without NRI Chart
FRA:UJ9 vs VRTX, REGN, ALNY: PE Ratio without NRI Comparison
For the Biotechnology subindustry, Shandong Boan Biotechnology Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Boan Biotechnology Co PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shandong Boan Biotechnology Co's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Shandong Boan Biotechnology Co's PE Ratio without NRI falls into.
Shandong Boan Biotechnology Co PE Ratio without NRI Calculation
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Shandong Boan Biotechnology Co's Share Price of today is €0.52.
For company reported semi-annually, Shandong Boan Biotechnology Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Shandong Boan Biotechnology Co (FRA:UJ9) has a PE Ratio without NRI of 520.00 as of Jul. 11, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Shandong Boan Biotechnology Co and its competitors. This is 504% above median its historical median of 86.11. Over the past decade, Shandong Boan Biotechnology Co's PE Ratio without NRI has ranged from 54.97 to 948.00. According to the industry distribution chart, Shandong Boan Biotechnology Co ranks #261 out of 266 companies in the Biotechnology industry, placing it in the top 98.1%.
Is Shandong Boan Biotechnology Co's PE Ratio without NRI too high?
Shandong Boan Biotechnology Co's current PE Ratio without NRI of 520.00 is 504% above median its 10-year median of 86.11. Over the past 10 years, this metric has ranged from a low of 54.97 to a high of 948.00. The Biotechnology industry median PE Ratio without NRI is 25.42. Shandong Boan Biotechnology Co's value of 520.00 is 1946% above this industry median. Based on the distribution chart, Shandong Boan Biotechnology Co ranks #261 out of 266 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shandong Boan Biotechnology Co has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Boan Biotechnology Co's PE Ratio without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shandong Boan Biotechnology Co ranks #261 out of 266 companies for PE Ratio without NRI. This places Shandong Boan Biotechnology Co in the lower half of its industry. The industry median PE Ratio without NRI is 25.42. Shandong Boan Biotechnology Co's value of 520.00 is 1946% above this benchmark. Historically, Shandong Boan Biotechnology Co's own PE Ratio without NRI has ranged from 54.97 to 948.00 over the past decade. While the company's 10-year median is 86.11 vs. the industry median of 25.42, Shandong Boan Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Biotechnology company?
The median PE Ratio without NRI among Biotechnology companies is 25.42, based on 266 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Boan Biotechnology Co's current PE Ratio without NRI of 520.00 is 1946% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Shandong Boan Biotechnology Co and its competitors. For the Biotechnology industry, the median PE Ratio without NRI is 25.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Boan Biotechnology Co's current PE Ratio without NRI is 520.00, which is 504% above median its own 10-year median of 86.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Boan Biotechnology Co stock overvalued right now?
Shandong Boan Biotechnology Co (FRA:UJ9) has a current PE Ratio without NRI of 520.00. The stock's GF Value™ is €1.70, compared to a current price of €0.52 — trading 69.4% below its estimated fair value. The current PE Ratio without NRI is 520.00, which is 504% above median its 10-year median of 86.11 and 1946% above the Biotechnology industry median of 25.42. Shandong Boan Biotechnology Co's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Shandong Boan Biotechnology Co (FRA:UJ9), the current PE Ratio without NRI is 520.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Boan Biotechnology Co (FRA:UJ9) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Boan Biotechnology Co stock appears to be undervalued.
The current stock price of €0.52 is trading 69.4% below its estimated GF Value™ of €1.70.
Key valuation signals for FRA:UJ9:
PE Ratio without NRI: 520.00 (504% above median its 10-year median of 86.11)
GF Value™: €1.70 vs. price of €0.52 (69.4% below fair value)
Industry Position: 1946% above the Biotechnology median (#261 of 266)
No single metric tells the full story. See the FRA:UJ9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Boan Biotechnology Co Business Description
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
39GF Score
Get the complete analysis for FRA:UJ9
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UJ9 has been successfully added to your 
